Elon Musk's Neuralink achieves a breakthrough as a brain chip is successfully implanted in the first human, signaling a new era in neurotechnology. (AP)
Elon Musk, the entrepreneur behind the tech startup Neuralink, has revealed the successful implantation of a brain chip in the first human test subject. The procedure took place on Sunday, with Musk reporting that the individual is currently in the recovery phase.
Sharing updates on his social media platform X, Musk expressed optimism about the initial results, noting promising neuron spike detection. The development follows the approval granted by the US Food and Drug Administration last year for human trials, a significant milestone after Neuralink conducted numerous tests on animals, a move that stirred controversy and led to accusations of animal abuse from rights groups.
According to Neuralink co-founder DJ Seo, the past two years have been dedicated to crafting a product suitable for human use. Seo emphasized the company's commitment to aiding real individuals, marking a shift from extensive animal testing.
The brain chip, equipped with 1,000 electrodes, aims to enable users to execute computer functions wirelessly through a "think-and-click" mechanism, driven solely by thought processes. In a recent announcement, the company sought participation from quadriplegics under 40 for the human trials, detailing a procedure involving the removal of part of the patient's skull by a surgeon, followed by the implantation of 64 threads lined with electrodes using a 7-foot-tall robot named R1. These electrodes are programmed to capture data related to brain activity associated with movement intentions.
The recorded neural signals will be transmitted back to Neuralink computers for decoding. DJ Seo outlined the company's short-term objective to develop a generalized brain interface, aiming to restore autonomy to individuals facing neurological challenges and unmet medical needs. In the long run, the goal is to make this technology accessible to billions, unlocking human potential beyond biological capabilities.
The specifics of the technology trial remain unclear, including the number of human participants involved. The comprehensive assessment will focus on the safety of both the robotic surgeon and the implanted chip, along with its overall functionality. The trial is anticipated to span six years, reflecting the thoroughness required to evaluate the technology thoroughly.
